Peter Riedell, MD, is assistant professor of medicine, director of clinical research for the Hematopoietic Cellular Therapy Program, and associate director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago. He specializes in the care of adults with lymphomas and chronic lymphocytic leukemia and has a special interest in the use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of these conditions. His expertise also includes stem cell transplant, allogeneic stem cell transplant, autologous stem cell transplant, and cellular therapy.
As an active clinical researcher, Dr. Riedell serves as the principal investigator on several national and international clinical trials evaluating the role of targeted therapies, stem cell transplantation, and cellular therapy in the treatment of lymphoma. He has been heavily involved in the development and implementation of therapies which harness a patient’s own immune system to fight cancer and his research aims to better characterize and enhance the safety and effectiveness of cellular therapy to improve patient outcomes.
Dr. Riedell holds roles on several national committees related to lymphoma and cellular therapy, and he is active in both patient and physician education. He also serves on the editorial board for peer-reviewed journals and is a member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO) and the American Society of Transplantation and Cellular Therapy (ASTCT).
Dr. Riedell is board certified in internal medicine, hematology, and medical oncology. He completed a fellowship in at Barnes-Jewish Hospital, completed his residency at Washington University, and earned his medical degree at the University of Tennessee.